Abstract |
Oral tinidazole, 500 mg twice daily for 5 days, was compared to triple sulfonamide cream inserted into the vagina twice daily for 7 days for the treatment of nonspecific vaginitis in a placebo-controlled, double-blind trial. At 1 and 3 weeks after treatment, 29 of 30 and 18 of 19 patients, respectively, who had been given tinidazole were cured, as compared to 16 of 27 and 6 of 14 patients, respectively, who had been given oral placebo together with a vaginal cream with or without sulfonamides (p less than 0.01 and p = 0.0015, respectively). At 3 weeks, five of nine women who had received vaginal sulfonamide cream and oral placebo had persistent nonspecific vaginitis, thus suggesting that it was not more effective than a vaginal placebo cream. Untreated nonspecific vaginitis and persistence of this syndrome were significantly associated with Gardnerella vaginalis, anaerobic gram-negative rods, clue cells, a vaginal pH of greater than or equal to 5.0, a succinate/ lactate peak heights ratio of greater than or equal to 0.3, and the absence of lactobacilli on a vaginal smear.
|
Authors | P Piot, E Van Dyck, P Godts, J Vanderheyden |
Journal | American journal of obstetrics and gynecology
(Am J Obstet Gynecol)
Vol. 147
Issue 1
Pg. 85-9
(Sep 01 1983)
ISSN: 0002-9378 [Print] United States |
PMID | 6351619
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Nitroimidazoles
- Sulfonamides
- Vaginal Creams, Foams, and Jellies
- Tinidazole
|
Topics |
- Administration, Oral
- Adult
- Clinical Trials as Topic
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Nitroimidazoles
(therapeutic use)
- Sulfonamides
(administration & dosage, therapeutic use)
- Tinidazole
(administration & dosage, therapeutic use)
- Vaginal Creams, Foams, and Jellies
- Vaginitis
(drug therapy, microbiology)
|